Although some patients with PD-L1+ NSCLC have benefited from the application of PD-1/PD-L1 monoclonal antibodies markedly 3, 4, the side effects and drug resistance were still of great concern to patients 4. Here, PDCD1 is linked to non-small cell lung carcinoma.